Gut bacteria treatment for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether a treatment that targets your gut bacteria (microbiome) can help fight triple-negative breast cancer before surgery. It is for people with newly diagnosed, untreated triple-negative breast cancer that has not spread far.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have triple-negative breast cancer (ER-negative, PR-negative, HER2-negative).
- Your tumor must be at least 2 cm in size (stage T2 or higher) and not have spread beyond the breast or nearby lymph nodes.
- You cannot be pregnant or breastfeeding.
- You should not be currently taking any other experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This trial tests a new personalized treatment approach (mRNA-lncRNA model) for people with low-risk, early-stage triple-negative breast cancer who have already had surgery. It aims to see if a less intense treatment can work just as well as standard care.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.